Key Events This Week
Jan 21: Death Cross formation signalling bearish trend
Jan 22: Technical downgrade with Mojo Grade shifting to Sell
Jan 23: Week closes at Rs.8,305.85 (+0.65%) outperforming Sensex
Feb 03
BSE+NSE Vol: 6.45 k

Astrazeneca Pharma India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a modest day gain of 0.97%, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential stabilisation. This article analyses the recent technical parameter changes, key momentum indicators, and how Astrazeneca’s performance compares with broader market benchmarks.
Read full news article
Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jan 21: Death Cross formation signalling bearish trend
Jan 22: Technical downgrade with Mojo Grade shifting to Sell
Jan 23: Week closes at Rs.8,305.85 (+0.65%) outperforming Sensex

Astrazeneca Pharma India Ltd has experienced a notable shift in price momentum, with technical indicators signalling a transition from mildly bearish to bearish trends. Despite a marginal day gain of 0.12%, the stock’s broader technical landscape suggests caution for investors amid weakening momentum and mixed signals from key oscillators and moving averages.
Read full news article
5 Jan: Downgrade to Sell rating amid technical weakness and valuation concerns
5 Jan: Mildly bearish technical shift confirmed by multiple momentum indicators
9 Jan: Week closes at ₹8,327.35, down 3.29% for the week

Astrazeneca Pharma India Ltd has seen its investment rating downgraded from Hold to Sell as of 2 January 2026, reflecting a shift in technical indicators and valuation metrics despite solid financial performance. The downgrade is primarily driven by a deteriorating technical trend, expensive valuation multiples, and mixed signals from financial and quality parameters, signalling caution for investors in the Pharmaceuticals & Biotechnology sector.
Read full news article
Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of early January 2026. This transition is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a cautious outlook for investors amid recent price declines and mixed market signals.
Read full news article
Astrazeneca Pharma India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend as of late December 2025. Despite a year-to-date return of 21.3%, outperforming the Sensex by a wide margin, recent technical indicators suggest a more cautious outlook for investors as mixed signals emerge across key momentum and trend metrics.
Read full news articleAstraZeneca Pharma India Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
AstraZeneca Pharma India Limited has informed the Exchange a copy of disclosure of Related Party Transactions for half year ended September 30, 2019 under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended
AstraZeneca Pharma India Limited has informed the Exchange regarding 'Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on November 13, 2019 in respect of the Unaudited Financial Results for the quarter ended September 30, 2019 approved in the Board Meeting of the Company held on November 11, 2019. '.
11 Feb 2026
Astrazeneca Pharma India Ltd has declared 1600% dividend, ex-date: 18 Jul 25
Astrazeneca Pharma India Ltd has announced 2:10 stock split, ex-date: 15 Jun 06
No Bonus history available
No Rights history available